Meeting
2022 ASCO Annual Meeting
Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.
Authors
Patrick Y. Wen
Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA
Patrick Y. Wen , John Frederick de Groot , James Battiste , Samuel A. Goldlust , James Stuart Garner , John Friend , Jeremy Andrew Simpson , Denise Damek , Alan Olivero , Timothy Francis Cloughesy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03522298
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2047)
DOI
10.1200/JCO.2022.40.16_suppl.2047
Abstract #
2047
Poster Bd #
385
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
First Author: Patrick Y. Wen
Poster
2024 ASCO Annual Meeting
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).
First Author: Dimitris Placantonakis
Poster
2023 ASCO Annual Meeting
A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma.
First Author: Shwetal Mehta
Poster
2023 ASCO Annual Meeting
BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.
First Author: Guilherme Fleury Perini